| Document |
Document Title |
|
WO/2024/114568A1 |
Provided are a heterocyclic substituted pyrimidine compound, a preparation method therefor, and a use thereof. Specifically, provided is a heterocyclic substituted pyrimidine compound represented by formula (I) or a pharmaceutically acce...
|
|
WO/2024/119067A1 |
The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
|
|
WO/2024/115549A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR8 receptor modulators in medicine.
|
|
WO/2024/114665A1 |
A substituted triazine-2,4-dione derivative intermediate and a preparation method therefor, the intermediate being a compound represented by formula (II), a salt thereof or an isomer thereof. The intermediate and the preparation method t...
|
|
WO/2024/117922A1 |
The subject of the invention is N-substituted derivatives of l-(l-phenyl-3-aryl)-lH- pyrazol-4-yl)methanamine with the general formula 1, where ¥ represents CH or N, R1 represents hydrogen, R2 represents no substituent, R3 represents hy...
|
|
WO/2024/115713A1 |
The present disclosure provides for techniques using BRISC deubiquitinating enzyme inhibitors of formula (I) for treating and/ or preventing systemic lupus erythematosus (SLE). Accordingly, the present disclosure provides for composition...
|
|
WO/2024/115438A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2024/118810A1 |
Provided herein are compounds that activate IRE1/XBP1s, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject...
|
|
WO/2024/114663A1 |
The present application relates to a solvate solid form of a triazinyl methyl cycloalkyl carboxylic acid derivative as represented by formula (I), a crystal form thereof, a pharmaceutical composition comprising same, a preparation method...
|
|
WO/2024/115509A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/114782A1 |
Disclosed herein are small-molecule modulators of spike protein, particularly modulators of betacoronavirus spike proteins, more particularly modulators of SARS-CoV-2 spike proteins. Also disclosed herein is the therapeutical use of the ...
|
|
WO/2024/113194A1 |
The invention provides novel phosphine oxide compounds that inhibit SHP2, compositions thereof, as well as methods of preparation thereof and for treating diseases associated with SHP2 (e.g., cancers).
|
|
WO/2024/116135A1 |
The present invention relates to a process for the preparation Bilastine (1). The process produces Bilastine (1) with greater than or equal to 99.9 % purity.
|
|
WO/2024/115465A1 |
A compound which is a PARP1 and/or PARP7 inhibitor has a structure: (I) R1, R3, R4, R10, R12, and R14 are each independently H or an organic group. R2, R5, R6, R7, R9, R11 are each independently absent, H, or an organic group. One R39 is...
|
|
WO/2024/115403A1 |
The invention relates to water vapor removal (dehumidification) with the use of ionic liquids. Membranes prepared from these ionic liquids can be useful for the removal of water vapor in isothermal processes, including dehumidification o...
|
|
WO/2024/111560A1 |
Provided is a compound having DDR1 inhibitory activity and represented by general formula (I), or a pharmaceutically acceptable salt or solvate thereof, and pharmaceutical use of the same.
|
|
WO/2024/112611A1 |
Provided are compounds that may bind a target protein, and result in modification of the target protein. The compounds may further bind a modifier protein. The modifier protein may carry out or enhance the modification of the target prot...
|
|
WO/2024/109660A1 |
The present disclosure discloses a novel class of compounds which act as selective CDK8/CDK19 inhibitors, pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and methods for treating ce...
|
|
WO/2024/109885A1 |
The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method there...
|
|
WO/2024/109917A1 |
The present invention relates to a triazole derivative and an application thereof in medicine, in particular to a compound described in general formula (I) or stereoisomers, tautomers, deuterates, solvates, prodrugs, metabolites, pharmac...
|
|
WO/2024/108765A1 |
Disclosed in the present invention is a spiro derivative as a KIF18A inhibitor, more specifically, a compound shown in formula II or a pharmaceutically acceptable salt thereof. The spiro derivative has KIF18A inhibitory activity and can ...
|
|
WO/2024/112692A1 |
Provided herein are compounds of formula (I) and salts and compositions thereof which find utility as modulators of Cbl-b in the treatment of various forms of cancer.
|
|
WO/2024/110215A1 |
Compounds of formula (I), (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and acaricides.
|
|
WO/2024/112287A1 |
The present invention relates to benzimidazole derivatives of formula (I) and their mPGES-1 inhibitory activity. The present invention also relates to pharmaceutical compositions containing these benzimidazole derivatives and their use i...
|
|
WO/2024/112612A1 |
Described herein are radiotherapeutics that target tumor cells expressing the neuropeptide Y1 receptor (NPY1R) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/109799A1 |
The present invention relates to a compound of general formula (I) or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method...
|
|
WO/2023/164612A9 |
Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disea...
|
|
WO/2024/110608A1 |
The present invention relates to a compound suitable for use as a kinase inhibitor.
|
|
WO/2024/109684A1 |
The present invention relates to use of a 8-hydroxyquinoline derivative, particularly, to use of a 8-hydroxyquinoline derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, a crystal form thereof, a so...
|
|
WO/2024/109688A1 |
The present invention relates to a pyrrole fused ring derivative or a stereoisomer thereof, a pharmaceutical composition thereof, and the pharmaceutical use thereof; and specifically relates to a pyrrole fused ring derivative as shown in...
|
|
WO/2024/108673A1 |
Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.
|
|
WO/2024/112621A1 |
The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said c...
|
|
WO/2024/109233A1 |
Provided in the present disclosure are a pyrimidoaromatic compound with a structure as shown in formula I', and a preparation method therefor and the use thereof. The compound has a significant inhibitory effect on the activities of KRAS...
|
|
WO/2024/109922A1 |
Disclosed are a bridged ring pyridazine compound and the use thereof, which compound and use belong to the technical field of chemical medicine. Provided is a bridged ring pyridazine compound as represented by formula I, which compound c...
|
|
WO/2024/109923A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound having a Formu...
|
|
WO/2024/112854A1 |
The present disclosure relates to RIPK2 inhibitors represented by structural formula (I). The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflamm...
|
|
WO/2024/109789A1 |
The present invention relates to a picolinamide compound as a Bruton's tyrosine kinase (BTK) inhibitor. Specifically, disclosed in the present invention are a 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridi
ne-3-carboxamide ...
|
|
WO/2024/112119A1 |
A TPD compound is disclosed.
|
|
WO/2024/109736A1 |
The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefor and a use thereof. The compound of the present application can significantly reduce the integr...
|
|
WO/2024/109871A1 |
The present disclosure relates to a pharmaceutically acceptable salt of a nitrogen-containing heterocyclic compound, a crystal form thereof, and a preparation method therefor. Specifically, the present disclosure provides a pharmaceutica...
|
|
WO/2024/108789A1 |
Provided is a diazafluorene compound. Diazafluorene is used as a basic structure, and an aryl or a heteroaryl is introduced onto the basic structure. The diazafluorene compound has a general formula as shown below: wherein X1-X8 respecti...
|
|
WO/2024/112853A1 |
Disclosed herein are compounds according to Formula I. (I). Compounds according to Formula I inhibit PKMYT1 and are useful for the treatment of cancer and other disease. The present invention also provides methods for making compounds as...
|
|
WO/2024/109788A1 |
The present invention relates to a PARP7 inhibitor compound shown in formula I, a preparation method therefor, and a use thereof in treating and/or preventing PARP7-mediated diseases.
|
|
WO/2024/109918A1 |
A compound as represented by general formula (I) or a stereoisomer, a racemate, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparat...
|
|
WO/2024/104292A1 |
The present disclosure relates to crystalline forms of (S) -4- (2, 2-difluoro-7- ( (5-methoxy-7-methyl-1H-indol-4-yl) methyl) -7-azaspiro [3.5] nonan-6-yl) benzoic acid and pharmaceutical compositions and uses of same.
|
|
WO/2024/107778A1 |
Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are useful for treating coronavirus infection via inhibition of the protease Mpro.
|
|
WO/2024/108131A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I), (II), (III), (IV), (V), or (VI) for killing cancer cell or inhibiting cancer cell proliferation. Further, the compounds and pharmaceutical compositi...
|
|
WO/2024/108100A1 |
The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
|
|
WO/2024/104441A1 |
The disclosure provides for compounds, compositions, and methods for modulating or inhibiting SIK.
|
|
WO/2023/091554A9 |
The invention provides new heteroaromatic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions includ...
|
